Cynapsus Therapeutics Inc. is a specialty pharmaceutical company developing a drug to treat the motor symptoms of Parkinson's disease.

[1] In September 2016, Sunovion (a subsidiary of Dainippon Sumitomo Pharma) announced it would acquire Cynapsus Therapeutics for approximately $624 million.

[2] Cynapsus is a specialty pharmaceutical company developing the only oral (sublingual) delivery of the only approved drug (apomorphine) to treat the motor symptoms of Parkinson's disease.

Cynapsus is focused on rapidly maximizing the value of APL-130277 by completing pivotal studies in advance of a New Drug Application expected to be submitted in 2015.

APL-130277 is a novel oral formulation of an approved drug for Parkinson's patients designed to deliver significant clinical benefits over the current marketed treatment.